SUBSCRIBE
SUBSCRIBE
News   Drug Development

AstraZeneca PLC, Johnson & Johnson Drugs for Schizophrenia May Exacerbate Loss of Brain Tissue, Study Finds

February 8, 2011 | 
1 min read
Bloomberg -- Anti-psychotic drugs from AstraZeneca Plc and Johnson & Johnson may lead to loss of brain tissue or exacerbate declines in brain volume caused by schizophrenia, a study in the Archives of General Psychiatry found.
Clinical research Postmarket research
AstraZeneca Pharmaceuticals LP Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Modern collage with human heart and hands stock illustration
Cardiovascular disease
Ionis’ Tryngolza ‘Game-Changing in Lowering Triglycerides, Cementing Case for FDA Filing
November 10, 2025
 · 
2 min read
 · 
Tristan Manalac
ransparent plastic tube being blocked by orange balls on blue background. Illustration of the concept of digestive disorders and difficulties on career paths
Cardiovascular disease
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy
November 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Goal concept. Human hand in dotted pop art style pointing on the target for red paper plane. Vector illustration
IgA nephropathy
Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing
November 7, 2025
 · 
2 min read
 · 
Tristan Manalac
The headquarters of Intellia Therapeutics, a brick building with two triangular shapes in its roof
Gene therapy
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
November 7, 2025
 · 
2 min read
 · 
Tristan Manalac